Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

5 Factors That Will Drive Growth in the Indian Pharma Sector in 2023

What are the five factors that will drive growth in the Indian pharma sector in 2023? Find out in this webinar and article.

Sanjay Shetgar, Vice President, Pharmaceutical Services, NSF International

NSF Vice President Sanjay Shetgar looks at five issues driving growth in the Indian pharmaceutical sector in 2023. He considers how proactive quality management, training and education, agile regulatory management, and other elements will drive the success of the third-largest pharmaceutical industry in the world.

Fast Facts About the Indian Pharmaceutical Industry

  • Indian pharma is the third largest pharma industry in the world.
  • India is the world’s largest vaccine producer.
  • It is the largest manufacturer and exporter of generic medicines.
  • It has the highest number of U.S. FDA-compliant plants outside the United States.
  • It supplies over 50% of Africa’s requirement for generics, almost 40% of generic demand in the United States and approximately 25% of all medicines in the United Kingdom.
  • Revenue for the Indian pharma industry is expected to reach $65 billion by 2024 and $130 billion by 2030.

The figures above show the excellent position the sector is in. Nevertheless, there are threats to the success of the industry. This webinar looks at two specific areas that threaten the industry’s success and that companies need to be mindful of as we head into 2023.

The two specific areas that are of most concern and that we will address in this webinar are:

  • Supply chain
  • Quality

Multiple global factors impact companies’ ability to get raw materials and ship finished products to their destinations. COVID-19-related delays have been prevalent in recent years. However, in the summer of 2022, climate-related issues have also impacted supply chains. There have been many reports in newspapers and other media on how rivers, particularly those used as important shipping routes for world trade, have shrunk, causing shipping companies to take lighter loads to help ensure their passage along the way.

For More Information Click Here...

Author Bio

Sanjay Shetgar

Sanjay Shetgar is Vice President of Pharmaceutical Services with NSF International. He has over 30 years of pharmaceutical management experience in both plant operations and corporate offices, working with Cipla, Dr.Reddy’s and Wockhardt in India. He has held senior positions as Vice President, Head Global Corporate Quality and Senior Vice President, Head Operations Quality with Dr.Reddy’s and Wockhardt.   His experience includes API & Intermediates, various Drug Product forms including Biologics.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024